Emcure Pharmaceuticals Limited IPO
- IPO Date03 Jul, 2024 to 05 Jul, 2024
- Listing Date10 Jul, 2024
- Face Value₹10 per share
- Issue Price₹960 to ₹1008 per share
- Lot Size14 Shares
- Minimum Investment₹14,112
- Listing AtBSE, NSE
- Total Issue Size1,93,65,346 Shares
(aggregating up to ₹1952.03 Cr) - Fresh Issue79,36,507 Shares
(aggregating up to ₹800.00 Cr)
- Offer for Sale1,14,28,839 Shares
(aggregating up to ₹1152.03 Cr) - Issue TypeBook Built Issue IPO
- Share holding pre issue18,08,52,116
- Shareholding post issue18,87,88,623
IPO Dates
Closing Date
05 Jul, 2024
Initiation of Refunds
09 Jul, 2024
Listing Date
10 Jul, 2024
03 Jul, 2024
Opening Date
08 Jul, 2024
Basis of Allotment
09 Jul, 2024
Credit of Shares
Emcure Pharmaceuticals Limited Lot Size
Investors can bid for a minimum of 14 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| S-HNI (Max) | 70 | 980 | ₹9,87,840 |
| Retail (Min) | 1 | 14 | ₹14,112 |
| B-HNI (Min) | 71 | 994 | ₹10,01,952 |
| S-HNI (Min) | 15 | 210 | ₹2,11,680 |
| Retail (Max) | 14 | 196 | ₹1,97,568 |
Emcure Pharmaceuticals Limited Promoter Holding
Satish Mehta and Sunil Mehta are the company promoters.
| Pre Issue Share Holding | Post Issue Share Holding |
|---|---|
| 98.9% | - |
Emcure Pharmaceuticals Limited COMPANY INFORMATION
Emcure Pharma IPO is a book built issue of Rs 1,952.03 crores. The issue is a combination of fresh issue of 0.79 crore shares aggregating to Rs 800.00 crores and offer for sale of 1.14 crore shares aggregating to Rs 1,152.03 crores. Emcure Pharma IPO opens for subscription on July 3, 2024 and closes on July 5, 2024. The allotment for the Emcure Pharma IPO is expected to be finalized on Monday, July 8, 2024. Emcure Pharma IPO will list on BSE, NSE with tentative listing date fixed as Wednesday, July 10, 2024. Emcure Pharma IPO price band is set at ₹960 to ₹1008 per share. The minimum lot size for an application is 14 Shares. The minimum amount of investment required by retail investors is ₹14,112. The minimum lot size investment for sNII is 15 lots (210 shares), amounting to ₹211,680, and for bNII, it is 71 lots (994 shares), amounting to ₹1,001,952. Kotak Mahindra Capital Company Limited, Axis Capital Limited, J.P. Morgan India Private Limited and Jefferies India Private Limited are the book running lead managers of the Emcure Pharma IPO, while Link Intime India Private Ltd is the registrar for the issue. Refer to Emcure Pharma IPO RHP for detailed information.
Incorporated in 1981, Emcure Pharmaceuticals Limited, an Indian pharmaceutical company, develops, manufactures, and globally markets a wide range of pharmaceutical products across several major therapeutic areas.
The company has been ranked 13th in domestic sales among pharmaceutical companies in India for MAT September 2023 and 4th in market share in its covered markets for the same period. Additionally, it is the leading pharmaceutical company in gynaecology and HIV antiviral therapeutic areas for the MAT September 2023.
In the six months ended September 30, 2023, and the Financial Year 2023, sales in India contributed 50.84% and 53.16% of the company's total revenue, respectively. The company's Domestic sales grew at a CAGR of 10.80% between September 2019 and September 2023, outperforming the Indian pharmaceutical market.
As of September 30, 2023, Emcure Pharma employed 552 scientists and operated five research facilities in India. They filed over 1,800 documents globally, including 204 in the EU and 133 in Canada. They had 201 granted patents, 33 pending patent applications, and submitted 102 drug master files.
Emcure Pharmaceuticals has 13 manufacturing facilities in India. These facilities can produce various pharmaceutical and biopharmaceutical products, including pills, liquids, injectables, and complex ingredients such as chiral molecules, iron molecules, and cytotoxic substances.
As of September 30, 2023, the company's marketing and distribution network in India was supported by over 5,000 field personnel who regularly interacted with healthcare providers. The distribution network included over 5,000 stockists, served by 37 carry-and-forward agents.
Analysis of EMCURE Pharmaceuticals Limited IPO
Overview of the IPO
Emcure Pharmaceuticals Limited, a key player in the pharmaceutical sector, is set to launch its Initial Public Offering (IPO) on July 3, 2024. The IPO includes both a fresh issue of equity shares and an offer for sale by existing shareholders, aiming to raise substantial capital to fuel growth and reduce debt.
Key Details of the IPO
The IPO comprises a fresh issue of up to ?8,000 million and an offer for sale of up to 11,428,839 equity shares. The offer includes a reservation for eligible employees, not exceeding 5% of the post-offer paid-up equity share capital. The promoters include prominent industry figures such as Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar, and Samit Satish Mehta.
- Issue Date: The IPO opens for subscription on July 3, 2024, and closes on July 5, 2024.
- Issue Size: The total offer size is not fully specified but includes a fresh issue of up to ?8,000 million and an offer for sale of up to 11,428,839 equity shares.
- Promoters: Key promoters include Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar, and Samit Satish Mehta.
- Share Reservation: The offer includes a reservation for eligible employees, not exceeding 5% of the post-offer paid-up equity share capital.
Pros of Investing in EMCURE Pharmaceuticals IPO
- Established Brand: Emcure Pharmaceuticals is a trusted name with a significant market presence.
- Growth Potential: The funds raised will aid in expansion and debt reduction.
- Experienced Management: The leadership team brings extensive industry experience.
- Diverse Product Portfolio: A wide range of products across therapeutic areas.
- Strong R&D Capabilities: Continuous innovation and product development.
Cons of Investing in EMCURE Pharmaceuticals IPO
- Market Uncertainty: The IPO's market reception and stock performance are uncertain.
- Regulatory Risks: The pharmaceutical sector is subject to stringent regulations.
- Intense Competition: Facing competition from both domestic and international companies.
- High Debt Levels: Current high debt levels pose potential risks.
- Operational Challenges: Risks related to manufacturing and supply chain.
FAQs About Emcure Pharmaceuticals Limited Ipo
Emcure Pharmaceuticals Limited IPO will open on 03 Jul, 2024 and close on 05 Jul, 2024. Investors must apply within this period to participate.
The Emcure Pharmaceuticals Limited IPO price band is set between ₹960.00 and ₹1008.00 per share. The minimum lot size is 14, requiring an investment of at least ₹14112.00.
The Emcure Pharmaceuticals Limited IPO shares are expected to be listed on 10 Jul, 2024, subject to regulatory approvals and final allotment.
You can track your Emcure Pharmaceuticals Limited IPO application status on the registrar’s website: Link Intime or KFintech using your PAN, application number, or DP ID
The Emcure Pharmaceuticals Limited IPO will be listed on major stock exchanges such as BSE, where you can trade shares once they are listed.